Arch Pharmalabs company logo

Arch Pharmalabs Share Price

PHYSICAL

PRIVATE LIMITED

Price Chart

High

₹135

Low

₹84.74

Return

-35.80%

Buy Sell Arch Pharmalabs Unlisted Shares

As of November 12, 2026, Arch Pharmalabs Unlisted Shares are available at ₹84.74 per share, with a face value of ₹10.00 per share, a 52-week high of ₹110.00 and a 52-week low of ₹84.00. The minimum lot size is 1850 shares, and the shares can be held in dematerialised form through NSDL and CDSL.

ISIN

info icon

INE182F01017

Face Value

info icon

10

Total Shares

info icon

15,19,23,076

Market Cap

info icon

1,287.4 Cr

Profit After Tax

info icon

124.95 Cr

Total Revenue

info icon

1,340.98 Cr

P/E

info icon

10.3

Sector

info icon

Health Care

Sub-sector

info icon

Pharmaceuticals

Category

info icon

Delisted

Cashflow - Operations

info icon

42.49 Cr

About Arch Pharmalabs

  • ​Arch Pharmalabsestablished on 2nd April 1993 is a pharmaceutical company aligned across two business verticals viz. Products and Services. Their Products business comprises manufacture and sale of APIs and Intermediates to innovator and generic pharmaceutical players in both domestic and international markets including the regulated markets. They have evolved their business and have, over the years, extended from manufacturing APIs and Intermediates to add CRAMS to their offerings, which has significant potential for the growth of our business.
  • The company operates three state-of-the-art facilities for API manufacturing: the Vitalife Site in Gurgaon, the Oncology Site in Tarapur, and the Dombivli Site in New Mumbai. Additionally, it has four facilities dedicated to intermediate manufacturing: the Merven Site and Watsol Site in Hyderabad, and the Badlapur Site and Taloja Site in Mumbai.
  • Arch Pharmalabs have a diversified portfolio product mix of more than 120 products (over 65 APIs and over 55 Intermediates) across various therapeutic segments including side chains of semi–Synthetic Isoxazole Penicillins under Antibiotics, Lipid Lowering Agents, Oncology, Anti-Platelet Agents, Anti-Asthmatic, Anti-Retroviral, Decongestant, Anti-Herpes, Anti-Malarial, NSAIDs, Anti-Anginal segments.

Want to See a Detailed Investment Analysis?

Explore in-depth financial analysis, performance metrics, and key disclosures.

Arch Pharmalabs Media

NCLT rejects JM Financial Asset Reconstruction's plea in Arch Pharmalabs case

NCLT rejects JM Financial Asset Reconstruction's plea in Arch Pharmalabs case

22 May 2024

• The Economic Times

FinMin reviews bankruptcy proceedings of Arch Pharma Labs, Among other high-profile cases.

FinMin reviews bankruptcy proceedings of Arch Pharma Labs, Among other high-profile cases.

05 May 2024

• Money control

Mitsui & Co buys additional 25% stake in Arch Pharmalabs for Rs 372 crore

Mitsui & Co buys additional 25% stake in Arch Pharmalabs for Rs 372 crore

16 Sep 2012

• economictimes

Frequently Asked Question (FAQs)

The annual report of Arch Pharmalabs Ltd is available in the annual report section.
Lock-in period of Arch Pharmalabs Unlisted Shares depends upon category of investors.
• 1. Venture Capital Funds or Alternate Investment Fund of Category -I or II, or Foreign Venture Capital Investor - lock-in Period of 6 months from the date of acquisition of Arch Pharmalabs Unlisted Shares.
• 2. Other Investors (include Retail, HNIs or Body Corporate) lock-in Period of 6 months from the date of listing of IPO of Arch Pharmalabs Unlisted Shares.
This new SEBI rule was introduced in the month of August-2021, wherein the SEBI has reduced the lock-in period previously from 1 year to 6 months to encourage more and more funds to be invested in startups which are going to public or IPO in near future. Reduction of lock-in is seen as big step and after that many PMS funds are advising their clients to invest in Pre-IPO shares to get the benefit of early stage investment.
Yes, buying and selling of unlisted shares in India is 100% legal.

Arch Pharmalabs

₹ 84.74